It is important to note that 53.5%, 47.5%, and 51.5% of the patients belonging to the HTA and CAD groups were treated with ACE inhibitors, beta-blockers, and statins, respectively (Table 1). The gene discussed is ACE; the disease is coronary artery disorder.